LB Pharmaceuticals Inc (LBRX) shareholders
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Kroin Joint filing with Deep Track Capital, LP (11.70%), Deep Track Biotechnology Master Fund, Ltd. (9.40%) | 3,352,804 | 11.70% | 13D (active) amendment | Feb 6, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (8.70%), Peter Kolchinsky (8.70%) and 1 more | 2,208,604 | 8.70% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Egen Atkinson Joint filing with Commodore Capital LP (6.80%), Commodore Capital Master LP (6.80%) and 1 more | 1,972,369 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| TCG Crossover GP II, LLC Joint filing with TCG Crossover Fund II, L.P. (6.40%), Chen Yu (6.40%) | 1,839,489 | 6.40% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 1,796,543 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (7.50%), Rajeev Shah (7.50%) and 1 more | 1,675,000 | 7.50% | 13G (passive) | Sep 12, 2025 |
| JPMorgan Chase & Co | 1,497,293 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Chen Yu Joint filing with TCG Crossover GP II, LLC (5.00%), TCG Crossover Fund II, L.P. (5.00%) | 1,447,310 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Johnson David Edward Joint filing with Caligan Partners LP (5.00%) | 1,438,070 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Tomer Kariv Joint filing with Pontifax Management 4 G.P. (2015) Ltd. (6.30%), Pontifax VI G.P. L.P. (6.30%) and 1 more | 1,411,681 | 6.30% | 13D (active) | Sep 12, 2025 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (5.00%), Ortav Yehudai (5.00%) | 1,268,265 | 5.00% | 13G (passive) | Dec 24, 2025 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (5.50%), Robert Egen Atkinson (5.50%) and 1 more | 1,225,000 | 5.50% | 13G (passive) | Sep 11, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LBRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 3,352,804 | 10.39% | $108.82M | – | 1.58% |
| BlackRock, Inc. | 2,734,305 | 8.48% | $88.74M | +263,460 | 0.00% |
| Ra Capital Management, L.P. | 2,208,604 | 6.85% | $71.68M | – | 0.62% |
| Nantahala Capital Management, LLC | 2,105,788 | 6.53% | $68.34M | +1,052,894 | 1.14% |
| Trails Edge Capital Partners, LP | 1,523,022 | 4.72% | $49.43M | +203,660 | 7.85% |
| Commodore Capital LP | 1,500,000 | 4.65% | $48.68M | – | 2.90% |
| JPMorgan Chase & Co | 1,497,293 | 4.64% | $48.87M | +69,725 | 0.00% |
| TCG Crossover Management, LLC | 1,447,310 | 4.49% | $46.97M | −392,179 | 1.13% |
| Caligan Partners LP | 1,438,070 | 4.46% | $46.67M | – | 2.20% |
| Spruce Street Capital LP | 1,376,159 | 4.27% | $44.66M | – | 8.76% |
| Vanguard Capital Management LLC | 971,165 | 3.01% | $31.52M | +76,512 | 0.00% |
| Balyasny Asset Management L.P. | 921,471 | 2.86% | $29.91M | −2,223 | 0.04% |
| Alyeska Investment Group, L.P. | 863,947 | 2.68% | $28.04M | – | 0.07% |
| Vivo Capital, LLC | 800,000 | 2.48% | $25.96M | – | 2.37% |
| Nan Fung Group Holdings Ltd | 630,657 | 1.95% | $20.47M | – | 15.57% |
| Geode Capital Management, LLC | 612,793 | 1.90% | $19.89M | +94,565 | 0.00% |
| State Street Corp | 602,028 | 1.87% | $19.54M | +97,655 | 0.00% |
| Logos Global Management LP | 585,000 | 1.81% | $18.99M | −330,000 | 0.82% |
| Goldman Sachs Group Inc | 576,456 | 1.79% | $18.71M | +212,657 | 0.00% |
| Jennison Associates LLC | 540,902 | 1.68% | $17.55M | +2,686 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 115 | 31M | 95.5% | 43 / 42 | 13 / 3 | 4M | 1M |
| Q1 2026 | 77 | 28M | 87.6% | 20 / 31 | 14 / 10 | 6M | 1M |
| Q4 2025 | 68 | 25M | 76.8% | 33 / 12 | 13 / 16 | 7M | 3M |
| Q3 2025 | 53 | 21M | 65.0% | 53 / 0 | 0 / 0 | 21M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
121 funds held LBRX in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LBRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| JPMorgan Small Cap Growth Fund | 692,905 | 2.15% | $22.49M | 0.86% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 672,000 | 2.08% | $21.81M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 581,750 | 1.80% | $18.88M | 0.02% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 567,627 | 1.76% | $15.88M | 0.27% | May 29, 2026 |
| Vanguard Extended Market Index Fund | 278,887 | 0.86% | $9.05M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 244,910 | 0.76% | $9.82M | 0.03% | Jul 31, 2026 |
| PGIM Jennison Health Sciences Fund | 231,150 | 0.72% | $6.47M | 0.47% | May 29, 2026 |
| JPMorgan Small Cap Blend Fund | 220,241 | 0.68% | $7.15M | 0.42% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 187,731 | 0.58% | $5.25M | 0.10% | May 31, 2026 |
| Calamos Timpani Small Cap Growth Fund | 144,326 | 0.45% | $5.78M | 0.75% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 126,232 | 0.39% | $3.53M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 115,659 | 0.36% | $3.23M | 0.01% | May 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 109,819 | 0.34% | $3.07M | 0.24% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 107,475 | 0.33% | $3.49M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 105,171 | 0.33% | $3.41M | 0.80% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Heather D. Turner | Chief Executive Officer, Director | – | – | Sep 12, 2025 |
| Susan Gani Kozauer | Chief Medical Officer | – | – | Oct 13, 2026 |
| Joseph M. Miller | Chief Financial Officer | – | – | Oct 13, 2026 |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | – | – | Dec 11, 2025 |
| Marc L. Panoff | Senior Vice President, Finance | 10,242 | 0.03% | Sep 29, 2025 |
| Gad Soffer | Chief Business Officer | – | – | Sep 12, 2025 |
| Anna Eramo | Chief Medical Officer | 3,585 | 0.01% | Sep 12, 2025 |
| Richard Anthony Silva | SVP, Technical Operations | – | – | Sep 12, 2025 |
| Robert R. Ruffolo | Director | 2,365 | 0.01% | Jun 5, 2026 |
| Rekha Hemrajani | Director | – | – | Jun 5, 2026 |
| William P. Kane Jr | Director | – | – | Jun 5, 2026 |
| Ran Nussbaum | Director | 1,411,681 | 4.38% | Jun 5, 2026 |
| Rebecca Luse | Director | – | – | Jun 5, 2026 |
| Robert A. Lenz | Director | – | – | Jun 5, 2026 |
| J. Scott Garland | Director | – | – | Jun 5, 2026 |
| Zachary Prensky | Director | 61,274 | 0.19% | Sep 12, 2025 |
| David Kroin | 10% owner | – | – | Aug 3, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 10% owner | – | – | Aug 3, 2026 |
| Deep Track Capital, LP | 10% owner | 3,352,804 | 10.39% | Aug 3, 2026 |
| Deep Track Special Opportunities Fund, LP | 10% owner | 666,666 | 2.07% | Feb 10, 2026 |
| Vida Ventures GP III, L.L.C. | 10% owner | 550,344 | 1.71% | Sep 16, 2025 |
| Arie Belldegrun | 10% owner | 1,434 | 0.00% | Sep 16, 2025 |
| Management 4 G.P. (2015) Ltd. Pontifax | 10% owner | 1,411,681 | 4.38% | Sep 16, 2025 |
| Ventures Management Co. LLC Vida | 10% owner | – | – | Sep 16, 2025 |
| Vida Ventures III, L.P. | 10% owner | – | – | Sep 16, 2025 |
| Vida Ventures III-A, L.P. | 10% owner | – | – | Sep 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ran Nussbaum Director | Sep 12, 2025 | Buy | +1,000,000 | $15.00 | $15.00M | 1,411,681 |
| Ran Nussbaum Director | Sep 12, 2025 | Conversion | +411,681 | – | – | 411,681 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | Sep 12, 2025 | Buy | +1,000,000 | $15.00 | $15.00M | 1,411,681 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | Sep 12, 2025 | Conversion | +411,681 | – | – | 411,681 |
| Vida Ventures GP III, L.L.C. 10% owner | Sep 12, 2025 | Conversion | +1,262 | – | – | 1,262 |
| Vida Ventures GP III, L.L.C. 10% owner | Sep 12, 2025 | Conversion | +547,648 | – | – | 547,648 |
| Vida Ventures GP III, L.L.C. 10% owner | Sep 12, 2025 | Buy | +767 | $15.00 | $11.51K | 2,029 |
| Vida Ventures GP III, L.L.C. 10% owner | Sep 12, 2025 | Buy | +332,566 | $15.00 | $4.99M | 880,214 |
| Deep Track Capital, LP 10% owner | Sep 12, 2025 | Buy | +666,666 | $15.00 | $10.00M | 666,666 |
| Deep Track Capital, LP 10% owner | Sep 12, 2025 | Buy | +2,000,000 | $15.00 | $30.00M | 2,686,138 |
| Deep Track Capital, LP 10% owner | Sep 12, 2025 | Conversion | +686,138 | – | – | 686,138 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LB Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 40,000 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zachary Prensky Former Officer | Jun 9, 2026 | 16,500 | $486.57K | Jun 9, 2026 | Owned Shares |
See a number that looks wrong?